UAB Digital Repository of Documents 2 records found  Search took 0.01 seconds. 
1.
8 p, 334.2 KB Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non-Small-Cell Lung Cancer : Retrospective Testing of Specimens from the EURTAC Trial / Benlloch, Susana (Pangaea Biotech) ; Botero, Maria Luisa (Pangaea Biotech) ; Beltran-Alamillo, Jordi (Pangaea Biotech) ; Mayo, Clara (Pangaea Biotech) ; Giménez-Capitán, Ana (Pangaea Biotech) ; de Aguirre, Itziar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Queralt, C (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramirez, Jose Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramón y Cajal, Santiago (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ; Klughammer, Barbara (F. Hoffmann-La Roche, Basel) ; Schlegel, Mariette (F. Hoffmann-La Roche, Basel) ; Bordogna, Walter (F. Hoffmann-La Roche, Basel) ; Chen, David (Genentech, South San Francisco, California) ; Zhang, Guili (Roche Molecular Systems, Pleasanton, California) ; Kovach, Barbara (Roche Molecular Systems, Pleasanton, California) ; Shieh, Felice (Roche Molecular Systems, Pleasanton, California) ; Palma, John F. (Roche Molecular Systems, Pleasanton, California) ; Wu, Lin (Roche Molecular Systems, Pleasanton, California) ; Lawrence, H. Jeffrey (Roche Molecular Systems, Pleasanton, California) ; Taron, Miquel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
The EURTAC trial demonstrated that the tyrosine kinase inhibitor (TKI) erlotinib was superior to chemotherapy as first-line therapy for advanced non-small cell lung cancers (NSCLC) that harbor EGFR activating mutations in a predominantly Caucasian population. [...]
2014 - 10.1371/journal.pone.0089518
PloS one, Vol. 9 (february 2014)  
2.
9 p, 287.7 KB The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer / Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Cirauqui, Beatriz (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Castellà Fernández, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Tapia, Gustavo (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ; Costa, Carla (Institut Universitari Dexeus) ; Giménez-Capitán, Ana (Institut Universitari Dexeus) ; Barnadas i Molins, Agustí (Institut d'Investigació Biomèdica Sant Pau) ; Ronco, Maria Sanchez (Universidad de Alcalá) ; Benlloch, Susana (Institut Universitari Dexeus) ; Taron, Miquel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
A fraction of sporadic breast cancers has low BRCA1 expression. BRCA1 mutation carriers are more likely to achieve a pathological complete response with DNA-damage-based chemotherapy compared to non-mutation carriers. [...]
2010 - 10.1371/journal.pone.0009499
PloS one, Vol. 5 (3 2010)  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.